ArticleThe Journal of clinical investigation1997
Production of the novel C-C chemokine MCP-4 by airway cells and comparison of its biological activity to other C-C chemokines.
Article in The Journal of clinical investigation, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 177 citations in OpenAlex.
- Dermal fibroblasts respond to IL-4 and IL-13 and promote T cell recruitment in atopic dermatitis.The Journal of clinical investigation · 2026Article
- Circulating inflammatory biomarkers and endometriosis lesion characteristics in the WisE consortium.npj women's health · 2025Article
- Functional Roles of Chemokine Receptor CCR2 and Its Ligands in Liver Disease.Frontiers in immunology · 2022Review
- CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4.International journal of molecular sciences · 2020Review
- CCL-11 or Eotaxin-1: An Immune Marker for Ageing and Accelerated Ageing in Neuro-Psychiatric Disorders.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Spring peaks and autumn troughs identified in peripheral inflammatory markers during the peripartum period.Scientific reports · 2019Article
- Elevated Plasma Chemokines for Eosinophils in Neuromyelitis Optica Spectrum Disorders during Remission.Frontiers in neurology · 2018Article
- Article
- Food-Induced Acute Pancreatitis.Digestive diseases and sciences · 2017Review
- Regulation of Eosinophil and Group 2 Innate Lymphoid Cell Trafficking in Asthma.Frontiers in medicine · 2017Article
- Elements Involved In Promoting Eosinophilic Gastrointestinal Disorders.Journal of genetic syndromes & gene therapy · 2015Article
- Deciphering Asthma Biomarkers with Protein Profiling Technology.International journal of inflammation · 2015Review
- The multiple faces of CCL13 in immunity and inflammation.Inflammopharmacology · 2013Review
- Increased CCL24/eotaxin-2 with postnatal ozone exposure in allergen-sensitized infant monkeys is not associated with recruitment of eosinophils to airway mucosa.Toxicology and applied pharmacology · 2011Article
- Chemokine expression by small sputum macrophages in COPD.Molecular medicine (Cambridge, Mass.) · 2011Article
- A convenient and sensitive allergy test: IgE crosslinking-induced luciferase expression in cultured mast cells.Allergy · 2010Article
- Transforming growth factor-β stimulates the expression of eotaxin/CC chemokine ligand 11 and its promoter activity through binding site for nuclear factor-κβ in airway smooth muscle cells.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2010Article
- Exacerbation of facial motoneuron loss after facial nerve axotomy in CCR3-deficient mice.ASN neuro · 2009Article
- Chemokines in tumor angiogenesis and metastasis.Cancer metastasis reviews · 2007Review
- Detection of human MCP-4/CCL13 isoforms by SELDI immunoaffinity capture.Journal of translational medicine · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 4 countries.
Funding
Abstract
Monocyte chemotactic protein-4 (MCP-4) is a newly identified C-C chemokine with potent eosinophil chemoattractant properties. We describe studies of its biological activity in vitro to induce chemotaxis of peripheral blood eosinophils and to induce histamine release from IL-3-primed peripheral blood basophils. MCP-4 and eotaxin caused a similar rise in eosinophil intracytoplasmic Ca2+ and complete cross-desensitization. MCP-4 also abolished the eosinophil Ca2+ response to MCP-3 and partially desensitized the response to macrophage inflammatory protein-1alpha. MCP-4 activated cell migration via either CCR2b or CCR3 in mouse lymphoma cells transfected with these chemokine receptors. MCP-4 inhibited binding of 125I-eotaxin to eosinophils and CCR3-transfected cells and inhibited 125I-MCP-1 binding to CCR2b-transfectants. MCP-4 mRNA was found in cells collected in bronchoalveolar lavage of asthmatic and nonasthmatic subjects and was prominently expressed in human lung and heart. MCP-4 mRNA was expressed in several human bronchial epithelial cell lines after cytokine stimulation. Pretreatment of BEAS-2B epithelial cells with the glucocorticoid budesonide inhibited MCP-4 mRNA expression. These features make MCP-4 a candidate for playing a role in eosinophil recruitment during allergic respiratory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.